A Phase 3 interventional study of Ruxolitinib cream and Vehicle in Non-segmental Vitiligo, sponsored by Incyte Corporation. Completed at 76 sites in 9 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-08-22.
Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing ruxolitinib in Vitiligo — 5 open to participants now, 5 under way, 4 of them phase 3. ruxolitinib · Vitiligo.
Among the 14 studies testing ruxolitinib in Vitiligo, this one is the 2nd largest by enrollment, is one of 2 that started in 2019, is one of 6 in phase 3, and was the 4th registered.
343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.
Browse Vitiligo studies →5 of the 14 studies testing ruxolitinib in Vitiligo are open now, in 12 countries. Recruiting first, the newest first:
Incyte Corporation · Sites in Argentina, Austria, Belgium and 11 more countries
Ages 6–11
Incyte Corporation · Sites in United States, Canada
Ages 2–11
Hospital Authority, Hong Kong · Sites in Hong Kong
Ages 18–85
Kafrelsheikh University · Sites in Egypt
Ages 12+
The Children's Hospital of Zhejiang University School of Medicine · Sites in China
Ages 2–11
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 7 · Phase 4 1
First in 2016; this study’s year is marked. 2 started in 2019.
This study's enrollment of 344 is above the median of 36 across 265 interventional studies indexed under Vitiligo.
Median enrollment 90 across the 14 interventional studies. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 14 have an industry lead sponsor. The 6 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
12 studies in Vitiligo by Incyte Corporation: 2 open now, 4 under way, 4 of them phase 3. Of 8 finished, 8 (100%) have results posted.
Among the 12 studies in Vitiligo by Incyte Corporation, this one is the 4th largest by enrollment, is one of 2 that started in 2019, is one of 7 in phase 3, and was the 3rd registered.
Incyte Corporation’s Vitiligo studies by the year they started, since 2017.
2 of the studies testing ruxolitinib in Vitiligo that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06804811Phase 3Incyte CorporationA Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo | 2027-04-30 |
| NCT07909668Kafrelsheikh UniversityTopical Ruxolitinib Versus Tacrolimus With Excimer Laser for Localized Vitiligo | 2026-12-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies testing ruxolitinib in Vitiligo, from their registry updates:
Among Incyte Corporation’s 12 in Vitiligo:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants applied ruxolitinib 1.5% cream twice daily (BID) for 24 weeks.
Drug: Ruxolitinib cream
Participants applied matching vehicle cream BID for 24 weeks.
Drug: Vehicle
Participants who completed the Week 24 assessments with no safety concerns could continue into the 28-week Treatment-Extension Period. Participants who applied ruxolitinib cream 1.5% BID during the Double-Blind Period continued to apply ruxolitinib cream 1.5% BID for an additional 28 weeks in the Treatment-Extension Period.
Drug: Ruxolitinib cream
Participants who completed the Week 24 assessments with no safety concerns could continue into the 28-week Treatment-Extension Period. Participants who applied vehicle cream BID during the Double-Blind Period applied ruxolitinib cream 1.5%m BID for 28 weeks in the Treatment-Extension Period.
Drug: Ruxolitinib cream · Drug: Vehicle
Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Also known as: INCB018424 cream
Vehicle cream is a topical formulation applied as a thin film to affected areas.
Percentage of Participants Achieving a ≥ 75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Week 24
An F-VASI75 responder achieved at least 75% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of body surface area \[BSA\]) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
Time frame: Baseline; Week 24
Percentage of Participants Achieving a ≥ 50% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI50) Score at Week 24
An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
Time frame: Baseline; Week 24
Percentage of Participants Achieving a ≥ 90% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI90) Score at Week 24
An F-VASI90 responder achieved at least 90% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
Time frame: Baseline; Week 24
Percentage of Participants Achieving a ≥ 50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50) Score at Week 24
A T-VASI50 responder achieved at least 50% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).
Time frame: Baseline; Week 24
Percentage of Participants Achieving a Vitiligo Noticeability Scale (VNS) of 4 or 5 at Week 24
The VNS is a patient-reported measure of vitiligo treatment success that is rated on a 5-point scale. The Baseline facial photograph was shown to the participants for reference, and a mirror was provided for the participants to assess the vitiligo on their face. The participant was asked to respond to the following query: Compared with before treatment, how noticeable is the vitiligo now? Responses: (1) more noticeable, (2) as noticeable, (3) slightly less noticeable, (4) a lot less noticeable, and (5) no longer noticeable.
Time frame: Baseline; Week 24
Percentage Change From Baseline in Facial Body Surface Area (F-BSA) at Week 24
F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline (BL) value minus BL value\]/BL value) X 100.
Time frame: Baseline; Week 24
Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.
Time frame: from the time of Informed Consent Form signing until at least 30 days after the last application of study drug (up to Week 24)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Treatment-Extension Period
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.
Time frame: from the completion of the Week 24 assessments until at least 30 days after the last application of study drug (up to Week 52 + 30 days)
Percentage of Participants Achieving a ≥ 25% Improvement in the Face Vitiligo Area Scoring Index (F-VASI25) Score at Week 24
An F-VASI25 responder achieved at least 25% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
Time frame: Baseline; Week 24
Percentage of Participants Achieving a ≥ %25, ≥ %50, ≥ 75%, and ≥ 90% Improvement in the Face Vitiligo Area Scoring Index (F-VASI25/50/75/90) Score at Week 52
An F-VASI25/50/75/90 responder achieved at least 25/50/75/90% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
Time frame: Baseline; Week 52
Percentage Change From Baseline in F-VASI at Week 24
F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.
Time frame: Baseline; Week 24
Percentage Change From Baseline in F-VASI at Week 52
F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.
Time frame: Baseline; Week 52
Percentage Change From Baseline in F-BSA at Week 52
F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.
Time frame: Baseline; Week 52
Percentage Change From Baseline in T-VASI at Week 24
T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.
Time frame: Baseline; Week 24
Percentage Change From Baseline in T-VASI at Week 52
T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.
Time frame: Baseline; Week 52
Percentage Change From Baseline in T-BSA at Week 24
T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.
Time frame: Baseline; Week 24
Percentage Change From Baseline in T-BSA at Week 52
T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.
Time frame: Baseline; Week 52
Percentage of Participants Achieving a ≥ 25%, ≥ 75%, and ≥ 90% Improvement in the Total Body Vitiligo Area Scoring Index (T-VASI25/75/90) Score at Week 24
A T-VASI25/75/90 responder achieved at least 25/75/90% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).
Time frame: Baseline; Week 24
Percentage of Participants Achieving a ≥ 25%, ≥ 50%, ≥ 75%, and ≥ 90% Improvement in the Total Body Vitiligo Area Scoring Index (T-VASI25/50/75/90) Score at Week 52
A T-VASI25/50/75/90 responder achieved ≥25/50/75/90% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).
Time frame: Baseline; Week 52
Percentage of Participants in Each Category of VNS During the Treatment Period (Double-Blind and Treatment-Extension Periods)
The VNS is a patient-reported measure of vitiligo treatment success that is rated on a 5-point scale. The Baseline facial photograph was shown to the participants for reference, and a mirror was provided for the participants to assess the vitiligo on their face. The participant was asked to respond to the following query: Compared with before treatment, how noticeable is the vitiligo now? Responses: (1) more noticeable, (2) as noticeable, (3) slightly less noticeable, (4) a lot less noticeable, and (5) no longer noticeable.
Time frame: Baseline; Week 24 and Week 52
Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 24
The DLQI is a 10-question validated questionnaire for use in participants aged 16 years and over to measure how much the skin problem has affected the participant over the previous 7 days. Each question is scored as: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. For Question 7, "Prevented work or studying" = 3. The DLQI was calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.
Time frame: Baseline; Week 24
Change From Baseline in DLQI at Week 52
The DLQI is a 10-question validated questionnaire for use in participants aged 16 years and over to measure how much the skin problem has affected the participant over the previous 7 days. Each question is scored as: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. For Question 7, "Prevented work or studying" = 3. The DLQI was calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.
Time frame: Baseline; Week 52
Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) During the Treatment Period (Double-Blind and Treatment-Extension Periods)
The DLQI is a 10-question validated questionnaire for use in participants aged 16 years and over to measure how much the skin problem has affected the participant over the previous 7 days. The CDLQI is the youth/children's version of the DLQI and was completed by adolescents aged ≥ 12 years to \< 16 years. Each question is scored as: very much = 3; quite a lot = 2; only a little = 1; not at all = 0; question unanswered = 0. For Question 7: "Prevented school" = 3. The CDLQI was calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.
Time frame: Baseline; Week 24 and Week 52
Trough Plasma Concentrations of Ruxolitinib at Weeks 4, 24, and 40
Trough plasma concentration was defined as the measurement of the plasma concentration of ruxolitinib before drug application.
Time frame: pre-dose at Weeks 4, 24, and 40
This study was conducted at 49 study centers in North America and Europe.
| Milestone | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID | Treatment-Extension Period: Ruxolitinib Cream 1.5% BID | Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|
| Started | 229 | 115 | 0 | 0 |
| Itt population | 229 | 115 | 0 | 0 |
| Itt population, excluding non-compliant site | 222 | 109 | 0 | 0 |
| Completed | 199 | 98 | 0 | 0 |
| Not completed | 30 | 17 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 11 | 6 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 10 | 8 | 0 | 0 |
| Withdrew: Discontinued treatment due to covid-19 pandemic | 3 | 1 | 0 | 0 |
| Withdrew: Non-compliance with attending study visits | 1 | 0 | 0 | 0 |
| Withdrew: Unable to attend study visits due to travel | 0 | 1 | 0 | 0 |
| Withdrew: Not treated | 1 | 0 | 0 | 0 |
| Milestone | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID | Treatment-Extension Period: Ruxolitinib Cream 1.5% BID | Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|
| Started | 0 | 0 | 199 | 98 |
| Completed | 0 | 0 | 178 | 79 |
| Not completed | 0 | 0 | 21 | 19 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 9 | 10 |
| Withdrew: Withdrawal by subject | 0 | 0 | 9 | 9 |
| Withdrew: Unable to perform safety follow-up visit | 0 | 0 | 1 | 0 |
An F-VASI75 responder achieved at least 75% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of body surface area \[BSA\]) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
| percentage of participants | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID |
|---|---|---|
| Percentage of Participants Achieving a ≥ 75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Week 24 | 30.9 | 11.4 |
An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
| percentage of participants | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID |
|---|---|---|
| Percentage of Participants Achieving a ≥ 50% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI50) Score at Week 24 | 51.4 | 20.9 |
An F-VASI90 responder achieved at least 90% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
| percentage of participants | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID |
|---|---|---|
| Percentage of Participants Achieving a ≥ 90% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI90) Score at Week 24 | 16.3 | 1.3 |
A T-VASI50 responder achieved at least 50% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).
| percentage of participants | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID |
|---|---|---|
| Percentage of Participants Achieving a ≥ 50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50) Score at Week 24 | 23.9 | 6.8 |
The VNS is a patient-reported measure of vitiligo treatment success that is rated on a 5-point scale. The Baseline facial photograph was shown to the participants for reference, and a mirror was provided for the participants to assess the vitiligo on their face. The participant was asked to respond to the following query: Compared with before treatment, how noticeable is the vitiligo now? Responses: (1) more noticeable, (2) as noticeable, (3) slightly less noticeable, (4) a lot less noticeable, and (5) no longer noticeable.
| percentage of participants | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID |
|---|---|---|
| Percentage of Participants Achieving a Vitiligo Noticeability Scale (VNS) of 4 or 5 at Week 24 | 20.5 | 4.9 |
F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline (BL) value minus BL value\]/BL value) X 100.
| percentage change | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID |
|---|---|---|
| Percentage Change From Baseline in Facial Body Surface Area (F-BSA) at Week 24 | -26.4 ± 2.57 | -7.0 ± 3.82 |
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.
| Participants | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period | 114 | 39 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.
| Participants | Treatment-Extension Period: Ruxolitinib Cream 1.5% BID | Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Treatment-Extension Period | 82 | 38 |
An F-VASI25 responder achieved at least 25% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
| percentage of participants | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID |
|---|---|---|
| Percentage of Participants Achieving a ≥ 25% Improvement in the Face Vitiligo Area Scoring Index (F-VASI25) Score at Week 24 | 63.9 | 32.0 |
An F-VASI25/50/75/90 responder achieved at least 25/50/75/90% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
| percentage of participants | Treatment-Extension Period: Ruxolitinib Cream 1.5% BID | Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID |
|---|---|---|
| F-VASI25 | 82.5 | 71.6 |
| F-VASI50 | 74.0 | 49.4 |
| F-VASI75 | 48.0 | 29.6 |
| F-VASI90 | 27.7 | 16.0 |
F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.
| percentage change | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID |
|---|---|---|
| Percentage Change From Baseline in F-VASI at Week 24 | -44.39 ± 2.85 | -15.80 ± 4.04 |
F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.
| percentage change | Treatment-Extension Period: Ruxolitinib Cream 1.5% BID | Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID |
|---|---|---|
| Percentage Change From Baseline in F-VASI at Week 52 | -63.75 ± 34.103 | -43.50 ± 47.509 |
F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.
| percentage change | Treatment-Extension Period: Ruxolitinib Cream 1.5% BID | Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID |
|---|---|---|
| Percentage Change From Baseline in F-BSA at Week 52 | -41.81 ± 35.694 | -23.45 ± 46.360 |
T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.
| percentage change | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID |
|---|---|---|
| Percentage Change From Baseline in T-VASI at Week 24 | -28.85 ± 1.96 | -8.99 ± 2.78 |
T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.
| percentage change | Treatment-Extension Period: Ruxolitinib Cream 1.5% BID | Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID |
|---|---|---|
| Percentage Change From Baseline in T-VASI at Week 52 | -46.80 ± 29.903 | -30.11 ± 30.315 |
T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.
| percentage change | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID |
|---|---|---|
| Percentage Change From Baseline in T-BSA at Week 24 | -14.23 ± 1.55 | -2.28 ± 2.19 |
T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.
| percentage change | Treatment-Extension Period: Ruxolitinib Cream 1.5% BID | Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID |
|---|---|---|
| Percentage Change From Baseline in T-BSA at Week 52 | -26.04 ± 28.481 | -13.54 ± 27.144 |
A T-VASI25/75/90 responder achieved at least 25/75/90% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).
| percentage of participants | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID |
|---|---|---|
| T-VASI25 | 50.2 | 21.2 |
| T-VASI75 | 8.0 | 1.8 |
| T-VASI90 | 1.0 | 0.0 |
A T-VASI25/50/75/90 responder achieved ≥25/50/75/90% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).
| percentage of participants | Treatment-Extension Period: Ruxolitinib Cream 1.5% BID | Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID |
|---|---|---|
| T-VASI25 | 76.8 | 53.1 |
| T-VASI50 | 49.2 | 22.2 |
| T-VASI75 | 20.9 | 8.6 |
| T-VASI90 | 6.8 | 1.2 |
The VNS is a patient-reported measure of vitiligo treatment success that is rated on a 5-point scale. The Baseline facial photograph was shown to the participants for reference, and a mirror was provided for the participants to assess the vitiligo on their face. The participant was asked to respond to the following query: Compared with before treatment, how noticeable is the vitiligo now? Responses: (1) more noticeable, (2) as noticeable, (3) slightly less noticeable, (4) a lot less noticeable, and (5) no longer noticeable.
| percentage of participants | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID | Treatment-Extension Period: Ruxolitinib Cream 1.5% BID | Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|
| Week 24, more noticeable | 8.5 | 11.2 | — | — |
| Week 24, as noticeable | 30.7 | 58.2 | — | — |
| Week 24, slightly less noticeable | 40.2 | 25.5 | — | — |
| Week 24, a lot less noticeable | 20.6 | 4.1 | — | — |
| Week 24, no longer noticeable | 0.0 | 1.0 | — | — |
| Week 52, more noticeable | — | — | 4.5 | 11.1 |
| Week 52, as noticeable | — | — | 16.4 | 25.9 |
| Week 52, slightly less noticeable | — | — | 46.3 | 49.4 |
| Week 52, a lot less noticeable | — | — | 32.2 | 13.6 |
| Week 52, no longer noticeable | — | — | 0.6 | 0.0 |
The DLQI is a 10-question validated questionnaire for use in participants aged 16 years and over to measure how much the skin problem has affected the participant over the previous 7 days. Each question is scored as: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. For Question 7, "Prevented work or studying" = 3. The DLQI was calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.
| scores on a scale | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID |
|---|---|---|
| Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 24 | -1.19 ± 0.30 | -0.59 ± 0.41 |
The DLQI is a 10-question validated questionnaire for use in participants aged 16 years and over to measure how much the skin problem has affected the participant over the previous 7 days. Each question is scored as: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. For Question 7, "Prevented work or studying" = 3. The DLQI was calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.
| scores on a scale | Treatment-Extension Period: Ruxolitinib Cream 1.5% BID | Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID |
|---|---|---|
| Baseline | 4.37 ± 4.485 | 5.38 ± 4.876 |
| Week 52 | -0.84 ± 3.976 | -1.15 ± 4.264 |
The DLQI is a 10-question validated questionnaire for use in participants aged 16 years and over to measure how much the skin problem has affected the participant over the previous 7 days. The CDLQI is the youth/children's version of the DLQI and was completed by adolescents aged ≥ 12 years to \< 16 years. Each question is scored as: very much = 3; quite a lot = 2; only a little = 1; not at all = 0; question unanswered = 0. For Question 7: "Prevented school" = 3. The CDLQI was calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.
| scores on a scale | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID | Treatment-Extension Period: Ruxolitinib Cream 1.5% BID | Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|
| Baseline | 1.29 ± 2.201 | 6.33 ± 10.116 | — | — |
| Week 24 | 0.00 ± 1.837 | -2.33 ± 8.505 | — | — |
| Week 52 | — | — | 1.19 ± 4.665 | -1.00 ± 4.583 |
Trough plasma concentration was defined as the measurement of the plasma concentration of ruxolitinib before drug application.
| nanomoles | Ruxolitinib Cream | Double-Blind Period: Vehicle Cream BID | Treatment-Extension Period: Ruxolitinib Cream 1.5% BID | Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|
| Week 4 | 61.0 ± 68.6 | — | — | — |
| Week 24 | 54.5 ± 79.1 | — | — | — |
| Week 40 | — | — | 57.0 ± 73.3 | 48.2 ± 57.0 |
Collected over from the time of Informed Consent Form signing until at least 30 days after the last application of study drug (up to Week 52 + 30 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vehicle Cream BID | 0/115 (0%) | 0/115 (0%) | 6/115 (5.2%) |
| Ruxolitinib Cream 1.5% BID | 0/326 (0%) | 6/326 (1.8%) | 56/326 (17.2%) |
| Event | Vehicle Cream BID | Ruxolitinib Cream 1.5% BID |
|---|---|---|
| Appendiceal abscessInfections and infestations | 0/115 | 1/326 |
| Coronary artery stenosisCardiac disorders | 0/115 | 1/326 |
| Joint dislocationInjury, poisoning and procedural complications | 0/115 | 1/326 |
| Papillary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/115 | 1/326 |
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 0/115 | 1/326 |
| UreterolithiasisRenal and urinary disorders | 0/115 | 1/326 |
| Event | Vehicle Cream BID | Ruxolitinib Cream 1.5% BID |
|---|---|---|
| COVID-19Infections and infestations | 2/115 | 24/326 |
| Application site acneGeneral disorders | 3/115 | 20/326 |
| NasopharyngitisInfections and infestations | 1/115 | 17/326 |
Baseline data are reported for members of the Safety Population, comprised of all participants who applied ruxolitinib cream or vehicle cream at least once. Treatment groups for this population were determined according to the actual treatment the participant applied on Day 1.
| Age, Continuous(years) | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID | Total |
|---|---|---|---|
| Mean | 38.4 ± 15.22 | 39.8 ± 12.12 | 38.9 ± 14.25 |
| Sex: Female, Male(Participants) | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID | Total |
|---|---|---|---|
| Female | 112 | 60 | 172 |
| Male | 116 | 55 | 171 |
| Race/Ethnicity, Customized(Participants) | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID | Total |
|---|---|---|---|
| White | 182 | 93 | 275 |
| Black/African American | 12 | 5 | 17 |
| Asian | 12 | 7 | 19 |
| American Indian/Alaska Native | 1 | 0 | 1 |
| Native Hawaiian/Pacific Islander | 2 | 0 | 2 |
| Not Reported | 3 | 3 | 6 |
| North African | 2 | 0 | 2 |
| White/Caucasian and Asian | 1 | 0 | 1 |
| Guyana | 1 | 0 | 1 |
| Cape Verdean | 1 | 1 | 2 |
| Persian | 1 | 0 | 1 |
| Middle Eastern | 3 | 0 | 3 |
| Arab/North-African | 1 | 0 | 1 |
| White/Black/Asian | 1 | 0 | 1 |
| Mexican | 2 | 1 | 3 |
| Jordanian | 1 | 0 | 1 |
| Arabic | 1 | 0 | 1 |
| Argentinian | 1 | 0 | 1 |
| Brazilian | 0 | 2 | 2 |
| Dominican Republic | 0 | 1 | 1 |
| Indo-Caribbean | 0 | 1 | 1 |
| Multi-National | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID | Total |
|---|---|---|---|
| Hispanic or Latino | 50 | 32 | 82 |
| Not Hispanic or Latino | 174 | 80 | 254 |
| Not Reported | 2 | 3 | 5 |
| Captured as "Other" | 2 | 0 | 2 |
| Face Vitiligo Area Scoring Index (F-VASI)(scores on a scale) | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID | Total |
|---|---|---|---|
| Mean | 0.900 ± 0.5248 | 0.834 ± 0.5233 | 0.878 ± 0.5245 |
| Facial Body Surface Area (F-BSA) Involvement(percentage of facial surface area) | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID | Total |
|---|---|---|---|
| Mean | 0.98 ± 0.570 | 0.92 ± 0.569 | 0.96 ± 0.569 |
| Total Body Vitiligo Area Scoring Index (T-VASI)(scores on a scale) | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID | Total |
|---|---|---|---|
| Mean | 6.844 ± 2.0574 | 7.022 ± 2.1986 | 6.904 ± 2.1043 |
| Total Body Surface Area (T-BSA) Involvement(percentage of total body surface area) | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID | Total |
|---|---|---|---|
| Mean | 7.44 ± 2.011 | 7.68 ± 2.040 | 7.52 ± 2.021 |
8 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2019 to primary completion in Mar 2021, 17 months.
Results were first posted in Sep 2022, 1 year 6 months after primary completion. A results delay was requested in Mar 2022.
Of 18 phase 3 interventional studies under Vitiligo, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 44. This study's 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib